Every change, on the record.
When we get something wrong — or when the data underneath an audit changes — we update the page and add an entry here. We do not quietly rewrite history.
Recent corrections
12 ENTRIES · NEWEST FIRSTTRIUMPH-3 and TRIUMPH-4 trial populations were transposed, the TRIUMPH-4 headline result and duration were wrong, and the FDA submission timeline was out of date.
Our article reported TRIUMPH-4 as showing 24% weight loss at 48 weeks in an obesity-plus-comorbidities population enriched for cardiovascular risk. TRIUMPH-4 ran 68 weeks in adults with obesity or overweight and knee osteoarthritis, and showed 28.7% average weight loss at 12 mg. The cardiovascular-disease population is TRIUMPH-3, which we had described as the osteoarthritis trial. The two were transposed. We also listed TRIUMPH-1 through TRIUMPH-4 as published as of May 2026, when TRIUMPH-2 and TRIUMPH-3 did not report until 23 July 2026, and we described a 2026 FDA submission target that Eli Lilly has since specified as a Q1 2027 Biologics License Application. A five-trial programme roster including a TRIUMPH-5 cardiovascular outcomes study could not be verified against Lilly's own announcements and was removed rather than rewritten. The article has been rewritten to cover all four reported readouts from Lilly's topline releases, and the retatrutide peptide page, dosing protocols, where-to-buy and retatrutide-versus-tirzepatide pages were updated to match.
Paradigm Peptides shutdown date corrected from December 2025 to March 2024, the charge description corrected, and unsourced investigation and customer-migration claims removed.
Our profile recorded Paradigm as having ceased operations in December 2025 following a federal plea. Operations actually ceased in March 2024 during the federal investigation, roughly twenty months earlier, with guilty pleas in 2025 and sentencing on 30 July 2026. We also described the charge as concerning SARMs products specifically and the peptide catalog as not being the formal target. Both defendants pleaded to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead, which covers the business as a whole, and the owner admitted forging laboratory certificates across the catalog. Separately, the earlier version carried customer-migration figures and an investigation timeline we could not trace to a primary document. Those passages were removed rather than rewritten. Primary source is the US Attorney's Office for the Northern District of Indiana announcement of 30 July 2026.
Limitless Biotech (formerly Limitless Life Nootropics) composite lowered from 91 to 76 to weight operating-history trust signals, and the profile retargeted to the current brand name.
Our April 2026 first-hand test order held up (96%+ retatrutide purity, clean cross-lab agreement), so COA quality and shipping subscores stayed high. But the composite had not accounted for the vendor's operating history: scam-labelled Reddit threads over billing/support disputes on the legacy brand, a pseudonymous owner-of-record, and a promo-seeded Trustpilot base. Support subscore moved 9.4 to 6.0 and composite 91 to 76 (green to navy). The profile name was updated from "Limitless Life Nootropics" to "Limitless Biotech" to match the current brand.
Refreshed with current data and reviewed for accuracy.
Refreshed with current data and reviewed for accuracy.
Refreshed with current data and reviewed for accuracy.
Refreshed with current data and reviewed for accuracy.
Refreshed with current data and reviewed for accuracy.
Refreshed with current data and reviewed for accuracy.
Refreshed with current data and reviewed for accuracy.
Updated last-tested date and shipping median after a reader-submitted COA contradicted our March finding.
A reader sent in a March 2026 third-party COA showing 96.4% purity on a batch we recorded at 91.2%. Re-tested an independent vial and confirmed the higher figure. Subscore for COA quality moved from 8.1 to 8.5; composite from 83 to 84.
Composite weighting clarified: shipping subscore moved from 25% to 20% to make room for an explicit 25% label-accuracy weight.
Earlier copy of the methodology page implied label accuracy was bundled into purity. We split the two and rebalanced. No vendor scores were retroactively adjusted; the next audit cycle uses the revised weights.
Our policy
3 CATEGORIESWe log every change in three categories:
- Factual — A specific number, date, or claim was wrong. Includes lab-result disagreements that meet our 5-percentage-point threshold.
- Methodological — The way we score, weight, or test changed. Earlier audits are not retroactively rescored unless explicitly noted.
- Transparency — A non-factual disclosure update: new affiliate relationship, editorial conflict, ownership change.
On the affected page, the correction appears as a dated note above the fold for at least 30 days, then moves into the “updated” metadata. The entry here is permanent.